Do analysts rate ASLN or ADXN?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ASLAN Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Addex Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is ASLN or ADXN more profitable?

Addex Therapeutics' return on equity of -134.76% beat ASLAN Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets ASLAN Pharmaceuticals N/A -8,454.87% -121.60% Addex Therapeutics N/A -134.76% -106.00%

Do analysts prefer ASLN or RDHL?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ASLAN Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Redhill Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is ASLN or RDHL more profitable?

Redhill Biopharma's return on equity of 0.00% beat ASLAN Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets ASLAN Pharmaceuticals N/A -8,454.87% -121.60% Redhill Biopharma N/A N/A N/A

Do analysts rate GRI or ASLN?

GRI Bio currently has a consensus target price of $21.00, indicating a potential upside of 1,011.11%. Given GRI Bio's stronger consensus rating and higher possible upside, analysts plainly believe GRI Bio is more favorable than ASLAN Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score GRI Bio 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 ASLAN Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is GRI or ASLN more profitable?

GRI Bio's return on equity of -134.03% beat ASLAN Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets GRI Bio N/A -134.03% -106.83% ASLAN Pharmaceuticals N/A -8,454.87% -121.60%

Do analysts prefer ASLN or INM?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ASLAN Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 InMed Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is ASLN or INM more profitable?

InMed Pharmaceuticals' return on equity of -156.08% beat ASLAN Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets ASLAN Pharmaceuticals N/A -8,454.87% -121.60% InMed Pharmaceuticals N/A -156.08% -123.90%

Do analysts prefer SBFM or ASLN?

Sunshine Biopharma presently has a consensus target price of $70.00, suggesting a potential upside of 6,442.06%. Given Sunshine Biopharma's stronger consensus rating and higher possible upside, research analysts plainly believe Sunshine Biopharma is more favorable than ASLAN Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sunshine Biopharma 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 ASLAN Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

ASLAN Pharmaceuticals (ASLN) Competitors

$0.60 0.00 (0.00%)

As of 09/11/2026

Compare

ASLN vs. ADXN, RDHL, GRI, INM, and SBFM

Should you buy ASLAN Pharmaceuticals stock or one of its competitors? ASLAN Pharmaceuticals's main competitors and comparable companies include Addex Therapeutics (ADXN), Redhill Biopharma (RDHL), GRI Bio (GRI), InMed Pharmaceuticals (INM), and Sunshine Biopharma (SBFM). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does ASLAN Pharmaceuticals compare to Addex Therapeutics?

ASLAN Pharmaceuticals (NASDAQ:ASLN) and Addex Therapeutics (NASDAQ:ADXN) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, earnings, analyst recommendations, valuation, media sentiment, profitability and risk.

Addex Therapeutics has lower revenue, but higher earnings than ASLAN Pharmaceuticals. Addex Therapeutics is trading at a lower price-to-earnings ratio than ASLAN Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ASLAN Pharmaceuticals	$12M	0.10	-$44.22M	-$21.92	N/A
Addex Therapeutics	$210K	20.17	-$8.12M	-$5.94	N/A

Addex Therapeutics' return on equity of -134.76% beat ASLAN Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ASLAN Pharmaceuticals	N/A	-8,454.87%	-121.60%
Addex Therapeutics	N/A	-134.76%	-106.00%

In the previous week, Addex Therapeutics had 2 more articles in the media than ASLAN Pharmaceuticals. MarketBeat recorded 2 mentions for Addex Therapeutics and 0 mentions for ASLAN Pharmaceuticals. Addex Therapeutics' average media sentiment score of 1.43 beat ASLAN Pharmaceuticals' score of 0.00 indicating that Addex Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
ASLAN Pharmaceuticals	Neutral
Addex Therapeutics	Positive

58.8% of ASLAN Pharmaceuticals shares are held by institutional investors. Comparatively, 16.1% of Addex Therapeutics shares are held by institutional investors. 4.7% of ASLAN Pharmaceuticals shares are held by insiders. Comparatively, 15.0% of Addex Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

ASLAN Pharmaceuticals has a beta of 1.4, suggesting that its stock price is 40% more volatile than the broader market. Comparatively, Addex Therapeutics has a beta of 1.47, suggesting that its stock price is 47% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ASLAN Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Addex Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Addex Therapeutics beats ASLAN Pharmaceuticals on 10 of the 13 factors compared between the two stocks.

How does ASLAN Pharmaceuticals compare to Redhill Biopharma?

ASLAN Pharmaceuticals (NASDAQ:ASLN) and Redhill Biopharma (NASDAQ:RDHL) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, media sentiment, risk, valuation, earnings and dividends.

In the previous week, Redhill Biopharma had 4 more articles in the media than ASLAN Pharmaceuticals. MarketBeat recorded 4 mentions for Redhill Biopharma and 0 mentions for ASLAN Pharmaceuticals. Redhill Biopharma's average media sentiment score of 0.72 beat ASLAN Pharmaceuticals' score of 0.00 indicating that Redhill Biopharma is being referred to more favorably in the news media.

Company	Overall Sentiment
ASLAN Pharmaceuticals	Neutral
Redhill Biopharma	Positive

58.8% of ASLAN Pharmaceuticals shares are held by institutional investors. Comparatively, 7.2% of Redhill Biopharma shares are held by institutional investors. 4.7% of ASLAN Pharmaceuticals shares are held by insiders. Comparatively, 6.8% of Redhill Biopharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

ASLAN Pharmaceuticals has a beta of 1.4, meaning that its stock price is 40% more volatile than the broader market. Comparatively, Redhill Biopharma has a beta of 4.96, meaning that its stock price is 396% more volatile than the broader market.

Redhill Biopharma has lower revenue, but higher earnings than ASLAN Pharmaceuticals. ASLAN Pharmaceuticals is trading at a lower price-to-earnings ratio than Redhill Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ASLAN Pharmaceuticals	$12M	0.10	-$44.22M	-$21.92	N/A
Redhill Biopharma	$290K	12.87	-$430K	$900.00	0.00

Redhill Biopharma's return on equity of 0.00% beat ASLAN Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ASLAN Pharmaceuticals	N/A	-8,454.87%	-121.60%
Redhill Biopharma	N/A	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ASLAN Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Redhill Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Redhill Biopharma beats ASLAN Pharmaceuticals on 11 of the 13 factors compared between the two stocks.

How does ASLAN Pharmaceuticals compare to GRI Bio?

GRI Bio (NASDAQ:GRI) and ASLAN Pharmaceuticals (NASDAQ:ASLN) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, earnings, media sentiment, analyst recommendations, profitability, risk and dividends.

GRI Bio's return on equity of -134.03% beat ASLAN Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GRI Bio	N/A	-134.03%	-106.83%
ASLAN Pharmaceuticals	N/A	-8,454.87%	-121.60%

In the previous week, GRI Bio had 13 more articles in the media than ASLAN Pharmaceuticals. MarketBeat recorded 13 mentions for GRI Bio and 0 mentions for ASLAN Pharmaceuticals. GRI Bio's average media sentiment score of 0.81 beat ASLAN Pharmaceuticals' score of 0.00 indicating that GRI Bio is being referred to more favorably in the media.

Company	Overall Sentiment
GRI Bio	Positive
ASLAN Pharmaceuticals	Neutral

GRI Bio currently has a consensus target price of $21.00, indicating a potential upside of 1,011.11%. Given GRI Bio's stronger consensus rating and higher possible upside, analysts plainly believe GRI Bio is more favorable than ASLAN Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GRI Bio	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
ASLAN Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

GRI Bio has higher earnings, but lower revenue than ASLAN Pharmaceuticals. GRI Bio is trading at a lower price-to-earnings ratio than ASLAN Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GRI Bio	N/A	N/A	-$11.96M	-$38.37	N/A
ASLAN Pharmaceuticals	$12M	0.10	-$44.22M	-$21.92	N/A

34.0% of GRI Bio shares are owned by institutional investors. Comparatively, 58.8% of ASLAN Pharmaceuticals shares are owned by institutional investors. 8.7% of GRI Bio shares are owned by insiders. Comparatively, 4.7% of ASLAN Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

GRI Bio has a beta of -1.24, meaning that its stock price is 224% less volatile than the broader market. Comparatively, ASLAN Pharmaceuticals has a beta of 1.4, meaning that its stock price is 40% more volatile than the broader market.

Summary

GRI Bio beats ASLAN Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

How does ASLAN Pharmaceuticals compare to InMed Pharmaceuticals?

ASLAN Pharmaceuticals (NASDAQ:ASLN) and InMed Pharmaceuticals (NASDAQ:INM) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, valuation, institutional ownership, risk, media sentiment, earnings, dividends and profitability.

InMed Pharmaceuticals has lower revenue, but higher earnings than ASLAN Pharmaceuticals. InMed Pharmaceuticals is trading at a lower price-to-earnings ratio than ASLAN Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ASLAN Pharmaceuticals	$12M	0.10	-$44.22M	-$21.92	N/A
InMed Pharmaceuticals	$4.94M	0.87	-$12.56M	-$2.89	N/A

58.8% of ASLAN Pharmaceuticals shares are held by institutional investors. Comparatively, 20.1% of InMed Pharmaceuticals shares are held by institutional investors. 4.7% of ASLAN Pharmaceuticals shares are held by insiders. Comparatively, 0.9% of InMed Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

InMed Pharmaceuticals' return on equity of -156.08% beat ASLAN Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ASLAN Pharmaceuticals	N/A	-8,454.87%	-121.60%
InMed Pharmaceuticals	N/A	-156.08%	-123.90%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ASLAN Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
InMed Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, InMed Pharmaceuticals had 4 more articles in the media than ASLAN Pharmaceuticals. MarketBeat recorded 4 mentions for InMed Pharmaceuticals and 0 mentions for ASLAN Pharmaceuticals. InMed Pharmaceuticals' average media sentiment score of 0.22 beat ASLAN Pharmaceuticals' score of 0.00 indicating that InMed Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
ASLAN Pharmaceuticals	Neutral
InMed Pharmaceuticals	Neutral

ASLAN Pharmaceuticals has a beta of 1.4, indicating that its share price is 40% more volatile than the broader market. Comparatively, InMed Pharmaceuticals has a beta of 0.98, indicating that its share price is 2% less volatile than the broader market.

Summary

InMed Pharmaceuticals beats ASLAN Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

How does ASLAN Pharmaceuticals compare to Sunshine Biopharma?

Sunshine Biopharma (NASDAQ:SBFM) and ASLAN Pharmaceuticals (NASDAQ:ASLN) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, analyst recommendations, media sentiment, dividends, risk, earnings, valuation and institutional ownership.

Sunshine Biopharma presently has a consensus target price of $70.00, suggesting a potential upside of 6,442.06%. Given Sunshine Biopharma's stronger consensus rating and higher possible upside, research analysts plainly believe Sunshine Biopharma is more favorable than ASLAN Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sunshine Biopharma	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
ASLAN Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

42.0% of Sunshine Biopharma shares are held by institutional investors. Comparatively, 58.8% of ASLAN Pharmaceuticals shares are held by institutional investors. 0.5% of Sunshine Biopharma shares are held by insiders. Comparatively, 4.7% of ASLAN Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

ASLAN Pharmaceuticals has a net margin of 0.00% compared to Sunshine Biopharma's net margin of -17.94%. Sunshine Biopharma's return on equity of -26.36% beat ASLAN Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sunshine Biopharma	-17.94%	-26.36%	-20.60%
ASLAN Pharmaceuticals	N/A	-8,454.87%	-121.60%

In the previous week, Sunshine Biopharma had 1 more articles in the media than ASLAN Pharmaceuticals. MarketBeat recorded 1 mentions for Sunshine Biopharma and 0 mentions for ASLAN Pharmaceuticals. Sunshine Biopharma's average media sentiment score of 1.91 beat ASLAN Pharmaceuticals' score of 0.00 indicating that Sunshine Biopharma is being referred to more favorably in the media.

Company	Overall Sentiment
Sunshine Biopharma	Very Positive
ASLAN Pharmaceuticals	Neutral

Sunshine Biopharma has a beta of 1.17, suggesting that its stock price is 17% more volatile than the broader market. Comparatively, ASLAN Pharmaceuticals has a beta of 1.4, suggesting that its stock price is 40% more volatile than the broader market.

Sunshine Biopharma has higher revenue and earnings than ASLAN Pharmaceuticals. Sunshine Biopharma is trading at a lower price-to-earnings ratio than ASLAN Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sunshine Biopharma	$36.31M	0.11	-$5.97M	-$10.15	N/A
ASLAN Pharmaceuticals	$12M	0.10	-$44.22M	-$21.92	N/A

Summary

Sunshine Biopharma beats ASLAN Pharmaceuticals on 11 of the 16 factors compared between the two stocks.

Get ASLAN Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ASLN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ASLN vs. The Competition

Export

Metric	ASLAN Pharmaceuticals	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.23M	$12.51B	$7.20B	$13.12B
Dividend Yield	N/A	2.64%	2.57%	11.71%
P/E Ratio	-0.03	797.24	273.84	25.39
Price / Sales	0.10	761.07	628.82	82.87
Price / Cash	N/A	14.86	28.42	34.96
Price / Book	-0.09	10.44	10.43	6.25
Net Income	-$44.22M	$2.84B	$3.49B	$358.19M
7 Day Performance	N/A	-3.15%	-2.11%	-1.43%
1 Month Performance	N/A	1.39%	0.64%	-2.72%
1 Year Performance	N/A	3.96%	24.61%	8.46%

ASLAN Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ASLN ASLAN Pharmaceuticals	N/A	$0.60 flat	N/A	N/A	$1.23M	$12M	N/A	30
ADXN Addex Therapeutics	1.0667 of 5 stars	$3.80 +7.8%	N/A	-67.4%	$4.67M	$210K	N/A	30	Short Interest Decrease Gap Up
RDHL Redhill Biopharma	1.5582 of 5 stars	$0.76 +1.9%	N/A	-57.3%	$4.63M	$286K	0.00	210	Short Interest Decrease
GRI GRI Bio	3.5884 of 5 stars	$2.11 +5.3%	$32.00 +1,419.5%	-96.3%	$4.56M	N/A	N/A	1	News Coverage Analyst Revision Gap Up
INM InMed Pharmaceuticals	1.2998 of 5 stars	$1.37 +1.3%	N/A	-39.7%	$4.55M	$4.94M	N/A	10	News Coverage Earnings Report Short Interest Decrease

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ASLN) was last updated on 9/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ASLAN Pharmaceuticals (ASLN) Competitors

ASLN vs. ADXN, RDHL, GRI, INM, and SBFM

How does ASLAN Pharmaceuticals compare to Addex Therapeutics?

Summary

How does ASLAN Pharmaceuticals compare to Redhill Biopharma?

Summary

How does ASLAN Pharmaceuticals compare to GRI Bio?

Summary

How does ASLAN Pharmaceuticals compare to InMed Pharmaceuticals?

Summary

How does ASLAN Pharmaceuticals compare to Sunshine Biopharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ASLN vs. The Competition

ASLAN Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ASLAN Pharmaceuticals (ASLN) Competitors

ASLN vs. ADXN, RDHL, GRI, INM, and SBFM

How does ASLAN Pharmaceuticals compare to Addex Therapeutics?

Which has better earnings & valuation, ASLN or ADXN?

Is ASLN or ADXN more profitable?

Does the media favor ASLN or ADXN?

Do institutionals and insiders have more ownership in ASLN or ADXN?

Which has more volatility & risk, ASLN or ADXN?

Do analysts rate ASLN or ADXN?

Summary

How does ASLAN Pharmaceuticals compare to Redhill Biopharma?

Does the media favor ASLN or RDHL?

Do insiders & institutionals believe in ASLN or RDHL?

Which has more risk and volatility, ASLN or RDHL?

Which has higher earnings & valuation, ASLN or RDHL?

Is ASLN or RDHL more profitable?

Do analysts prefer ASLN or RDHL?

Summary

How does ASLAN Pharmaceuticals compare to GRI Bio?

Is GRI or ASLN more profitable?

Does the media refer more to GRI or ASLN?

Do analysts rate GRI or ASLN?

Which has stronger valuation and earnings, GRI or ASLN?

Do institutionals and insiders have more ownership in GRI or ASLN?

Which has more volatility & risk, GRI or ASLN?

Summary

How does ASLAN Pharmaceuticals compare to InMed Pharmaceuticals?

Which has better earnings and valuation, ASLN or INM?

Do institutionals & insiders believe in ASLN or INM?

Is ASLN or INM more profitable?

Do analysts prefer ASLN or INM?

Does the media favor ASLN or INM?

Which has more volatility & risk, ASLN or INM?

Summary

How does ASLAN Pharmaceuticals compare to Sunshine Biopharma?

Do analysts prefer SBFM or ASLN?

Do insiders & institutionals have more ownership in SBFM or ASLN?

Is SBFM or ASLN more profitable?

Does the media prefer SBFM or ASLN?

Which has more risk and volatility, SBFM or ASLN?

Which has preferable earnings & valuation, SBFM or ASLN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ASLN vs. The Competition

ASLAN Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools